Literature DB >> 7777201

Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia.

K Yamada1, K Kono, H Umegaki, K Yamada1, A Iguchi, T Fukatsu, N Nakashima, H Nishiwaki, Y Shimada, Y Sugita.   

Abstract

We examined IL-6 levels in the cerebrospinal fluid (CSF) of patients clinically diagnosed with Alzheimer-type dementia (ATD) and with vascular dementia (VD) and of age-matched normal subjects. The IL-6 levels in the CSF of ATD, but not VD patients, were significantly decreased. In the early onset ATD patients (disease onset < 65 years), IL-6 levels were reduced to 21% of the control level. The IL-6 levels in the CSF were not associated with the severity of the dementia or the duration of the disease since the identification of the first symptoms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777201     DOI: 10.1016/0304-3940(95)11318-q

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  Intrathecal levels of IL-6 in Alzheimer's disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

2.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 3.  Physiological and pathological roles of interleukin-6 in the central nervous system.

Authors:  D L Gruol; T E Nelson
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

Review 4.  Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.

Authors:  Wen-Ying Wang; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-06

5.  Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.

Authors:  Muge Akinci; Cleofé Peña-Gómez; Gregory Operto; Sherezade Fuentes-Julian; Carme Deulofeu; Gonzalo Sánchez-Benavides; Marta Milà-Alomà; Oriol Grau-Rivera; Nina Gramunt; Arcadi Navarro; Carolina Minguillón; Karine Fauria; Ivonne Suridjan; Gwendlyn Kollmorgen; Anna Bayfield; Kaj Blennow; Henrik Zetterberg; José Luis Molinuevo; Marc Suárez-Calvet; Juan Domingo Gispert; Eider M Arenaza-Urquijo
Journal:  Neurology       Date:  2022-08-02       Impact factor: 11.800

6.  Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Daniela Galimberti; Eliana Venturelli; Chiara Fenoglio; Ilaria Guidi; Chiara Villa; Luigi Bergamaschini; Francesca Cortini; Diego Scalabrini; Pierluigi Baron; Carlo Vergani; Nereo Bresolin; Elio Scarpini
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

7.  CSF Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  A Anoop; Pradeep K Singh; Reeba S Jacob; Samir K Maji
Journal:  Int J Alzheimers Dis       Date:  2010-06-23

8.  Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease.

Authors:  Sonia Chalbot; Henrik Zetterberg; Kaj Blennow; Tormod Fladby; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Clin Chem       Date:  2009-10-22       Impact factor: 8.327

Review 9.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

10.  Distinct cytokine profiles in human brains resilient to Alzheimer's pathology.

Authors:  Isabel Barroeta-Espar; Laura D Weinstock; Beatriz G Perez-Nievas; Avery C Meltzer; Michael Siao Tick Chong; Ana C Amaral; Melissa E Murray; Krista L Moulder; John C Morris; Nigel J Cairns; Joseph E Parisi; Val J Lowe; Ronald C Petersen; Julia Kofler; Milos D Ikonomovic; Oscar López; William E Klunk; Richard P Mayeux; Matthew P Frosch; Levi B Wood; Teresa Gomez-Isla
Journal:  Neurobiol Dis       Date:  2018-10-15       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.